Company attributes
Other attributes
Juventas Therapeutics is a biotechnology company developing non-viral gene therapies capable of activating natural processes within the body for healing and repair. The company was founded by Rahul Aras in 2007 and is headquartered in Cleveland, Ohio.
Their first therapeutic product candidate JVS-100 is a non-viral gene therapy expressing a signalling protein that can recruit naturally occurring stem cells and promote tissue repair in a broad range of disease states. Juventas is currently completing a Phase 2b study with JVS-100 in patients with advanced peripheral artery disease.
On September 30, 2008 Juventus Therapeutics completed a seed funding round with $300,000 in funding from JumpStart Inc.
On October 23, 2008 Juventus Therapeutics completed a series A funding round with $7.7 million in funding from Triathlon Medical Venture Partners and Early Stage Partners.
On July 16, 2012 Juventus Therapeutics completed their series B funding round with $22.2 million in funding from Triathlon Medical Venture Partners (lead investor), New Science Ventures (lead investor), Takeda Ventures, Reservoir Venture Partners, North Coast Angel Fund, New Science Ventures, Fletcher Spaght, and Early Stage Partners.
